Štěpána Boukalová Mechanisms of activation and modulation of vanilloid TRP channels TRPV1 and TRPV3 are thermosensitive ion channels from the vanilloid subfamily of TRP receptors. TRPV1, which is primarily expressed in nociceptive sensory neurons, is an important transducer of painful stimuli and is also involved in the detection of noxious heat. TRPV3 is expressed mainly in the skin where it regulates proliferation and differentiation of keratinocytes. Similarly to voltage-dependent potassium (Kv) channels, TRP receptors are comprised of four subunits, each with six transmembrane segments (S1-S6). Using mutational approach, we tried to elucidate the role of S1 in TRPV1 functioning. Our results indicate that the extracellular portion of S1 plays a crucial role in TRPV1 gating. TRPV1 channels with a conservative mutation of positively charged residue in this region (R455K substitution) were overactive. However, they were neither activated nor potentiated by low pH; on the contrary, protons stabilized the closed conformation of this mutant channel. Very similar phenotypic properties were found in other TRPV1 mutants with substitution in S4/S5-S5 region and in the pore helix. In Kv channels, extracelular portion of S1 forms a small contact surface with the pore helix, which allows efficient transmission of...

O Receptor do Fator de Crescimento Epidérmico (do inglês, EGFR) é uma proteína de membrana celular que consiste em um domínio extracelular para o acoplamento do ligante e em um domínio intracelular apresentando sítio catalítico de tirosinoquinase. Em ~40% dos GBMs primários é observada a amplificação de EGFR resultando na sua hiperexpressão, o que raramente ocorre em GBM secundário. Mais da metade dos casos de GBM com amplificação do receptor está associado com rearranjo do gene, uma forma deletada de EGFR (EGFRvIII). Adicionalmente, o receptor de interleucina 13 alfa-2 (IL-13R 2), apresenta-se abundante e especificamente hiperexpresso em gliomas de alto grau, em particular, GBM. O objetivo do presente estudo é analisar a expressão, amplificação, e deleção de EGFR em astrocitomas, bem como a coexpressão entre esse gene e o da IL-13R 2. Foram analisadas 145 astrocitomas (22 astrocitomas pilocíticos (AP); 22 astrocitomas grau II (AGII); 17 astrocitomas anaplásico (AA); e 84 GBM) e 17 tecidos cerebrais não tumorais provenientes de cirurgia de epilepsia. A deleção EGFRvIII foi analisada por RT-PCR, e confirmada por PCR em tempo real (RQ-PCR). A expressão relativa de EGFR e IL-13R 2 foi estudada por RQ-PCR utilizando-se o método SYBR Green, comparado ao tecido não tumoral, e normalizado para os genes de referência endógena, HPRT e Gus- . A amplificação de EGFR foi também determinada por RQ-PCR com relação ao gene da beta-hemoglobina, descrito como um gene de cópia única. Foi realizada imunohistoquímica para analisar a expressão da proteína EGFR. A deleção EGFRvIII foi somente encontrada em GBM (19/84, 23%), demonstrando a exclusividade dessa alteração num grau tumoral de maior malignidade e uma diminuição da sobrevida desses pacientes (p = 0,030). A hiperexpressão de EGFR foi encontrada em 88 casos (61%), correspondendo a 50% de GBM, 88% de AA, e interessantemente em 77% de AGII e 64% de AP. Da mesma maneira, a hiperexpressão de IL-13R 2 foi encontrada em 62 casos (43%), correspondendo a 48% de GBM, 29% de AA, 18% de AGII e, surpreendentemente em 59% de AP. Embora tenha havido um aumento de expressão de ambos os genes em todos os graus de astrocitomas, não houve coexpressão dos mesmos. A amplificação de EGFR foi observada em 29 casos (20%) correspondendo a 31% de GBM e ainda um caso para cada um dos demais graus de astrocitomas, sendo que dos 29 casos amplificados, 21 pacientes eram mais velhos que 45 anos (p < 0,001) e 50% dos casos de GBM com amplificação de EGFR, apresentaram simultaneamente EGFRvIII. Adicionalmente, o acúmulo citoplasmático da proteína foi detectado em 74 casos (51%), correspondendo a 55% de GBM, 47% de AA, 54,5% de AGII e 37% de AP, além de um acúmulo nuclear detectado em 15% dos casos de astrocitomas difusamente infiltrativos. Assim, a alta freqüência de hiperexpressão dos genes estudados em todos os graus de astrocitomas, principalmente a amplificação de EGFR e a presença da deleção EGFRvIII foram observados entre os astrocitomas de alto grau, especialmente em GBM. Os resultados apresentados contribuem para um melhor direcionamento no futuro em métodos terapêuticos específicos, salientando a importância da análise de expressão molecular, protéica e das alterações mutacionais que envolvem genes candidatos, em particular, EGFR e IL-13R 2 / Epidermal Growth Factor Receptor, EGFR is a transmembrane protein consisting of an extracellular EGF-binding domain and an intracellular domain with ligand-activated tyrosine kinase activity. In ~40% of primary GBM is observed amplification leading to overexpression of EGFR, but rarely in secondary GBM. Over the half of primary GBM with EGFR amplification is associated to gene rearrangement, a deleted form of EGFR (EGFRvIII). Additionally, the interleukin-13 alpha 2 receptor (IL13R 2) is abundant and specifically overexpressed in high-grade gliomas, particularly in GBM. The aim of the present study is to analyze the EGFR expression, amplification, and deletion in astrocytomas as well as its coexpression with IL13R 2. We have analyzed 145 surgical astrocytoma samples (22 pilocytic astrocytomas (PA); 22 low-grade astrocytomas (LGA); 17 anaplastic astrocytomas (AA); and 84 GBM) and 17 non-neoplastic brain tissue from epilepsy surgery. EGFRvIII deletion was analyzed by RT-PCR, and also confirmed by real time PCR (RQ-PCR). The relative EGFR and IL-13R 2 expression was studied by RQ-PCR using SYBR Green method, compared to non-neoplastic tissue, normalized for HPRT and Gus- genes. The EGFR amplification was also determined by RQ-PCR relative to the hemoglobin beta gene, described as a single copy gene. Immunohistochemistry was performed to analyze the protein expression in tumor samples. The EGFRvIII deletion was found only in GBM cases (19/84, 23%) demonstrating the exclusivity of this alteration in higher tumor grade and survival was decreased in these patients (p = 0.030). EGFR overexpression was found in 88 cases (61%), corresponding to 50% of GBM, 88% of AA, and interestingly in 77% of LGA and 64% of PA. In the same way, the overexpression of IL-13R 2 was found in 62 cases (43%), corresponding to 48% of GBM, 29% of AA, 18% of LGA and, surprising in 59% of PA. Although increased expression of both genes was demonstrated in all astrocytoma grades, it was no coexpression of the genes. The amplification was observed in 29 cases (20%) corresponding to 31% of GBM and only one case each of PA, LGA and AA. Among 29 cases with EGFR amplification, 21 patients were older than 45 years (p < 0.001) and 50% of GBM with EGFR amplification presented simultaneously the EGFRvIII. Moreover, the EGFR cytoplasmic accumulation was detected in 74 cases (51%), corresponding to 55% of GBM, 47% of AA, 54.5% of LGA and 37% of PA, and nuclear accumulation was detected in 15% of diffusely infiltrative astrocytomas. Thus, the high overexpression frequency of the genes studied in all grades of astrocytomas, mainly the EGFR amplification and presence of EGFRvIII deletion were observed among high-grade astrocytomas, mainly in GBM. The present results contribute to better tailoring specific future therapeutical approach in patients with astrocytomas, pointing out the importance of the molecular, protein expressions and mutational analyses of candidates genes, in particular, EGFR and IL-13R 2

A amplificação gênica mais freqüente em câncer de mama é a do oncogene ERBB-2, observada em aproximadamente 30% dos tumores de mama e que está relacionada com menor intervalo livre de doença e sobrevida total das pacientes com câncer de mama. O ERBB-2 ativa importantes vias de sinalização celular, incluindo as vias MAPK e PI3K. Utilizando PCR em tempo real analisou-se o efeito do EGF e da HRG na regulação da expressão dos genes ANP32B, MATR3, ATAD4, NDRG1, ACTN1, SPARC, TPM1 e CENPH, nas células HB4a, C5.2 e SKBr3, que expressam diferentes níveis de ERBB2. Avaliou-se também o perfil de expressão destes transcritos após a supressão do ERBB2 pela técnica de siRNA nas células C5.2. O tratamento com EGF modulou de forma diferente a expressão dos genes estudados nas células HB4a, C5.2 e SKBr3. Nas células HB4a e SKBr3 a HRG também regulou a expressão dos genes acima. Após a transfecção das células C5.2 com siERBB2 houve alteração na expressão dos genes ATAD4, NDRG1, ACTN1, SPARC, MATR3, CENPH e TPM1. / The more frequent genic amplification observed in breast cancer is that of the ERBB2 oncogene, which occurs in approximately 30% of the breast cancers, and is associated with lower disease-free interval and survival of all patients with breast cancer. The ERBB-2 protein activates important cell signaling pathways such as MAPK and PI3K. Using real time PCR, it was investigated the effect of EGF and HRG on ANP32B, MATR3, ATAD4, NDRG1, ACTN1, SPARC, TPM1 and CENPH transcripts regulation in the HB4a, C5.2 and SKBr3 cell, that express different levels of ERBB2. It was also evaluated the expression profile of these transcripts in the C5.2 cell line after the suppression of ERBB2 expression by the siRNA technique. The treatments with EGF modulate differently the expression of the analysed transcripts in HB4a, C5.2 and SKBr3 cells. In HB4a and SKBr3 cells the treatments with HRG also modulate the expression of the transcripts above. The C5.2 cells transfected with siERBB2 showed alteration in the expression of ATAD4, NDRG1, ACTN1, SPARC, MATR3, CENPH and TPM1 transcripts.

Danos ao sistema nervoso central (SCN) resultam em perda de conexões axonais, das funções motoras e sensoriais. Uma das estratégias para seu reparo é o transplante de células-tronco mesenquimais (CTMs). Porém essa alternativa requer uma adequada via de aplicação. Nesse sentido, o uso de matrizes alinhadas pode ser usado para apoiar o crescimento e diferenciação das CTMs e, quando incorporadas com fatores de crescimento, otimizam o processo de regeneração tecidual. O objetivo desse trabalho foi avaliar a diferenciação neural das CTMs cultivadas sobre matrizes de nanofibras orientadas com o fator de crescimento epidermal (EGF) incorporado. Os scaffolds com fibras alinhadas foram produzidos por electrospinning de emulsão e avaliados conforme a sua morfologia, o diâmetro das nanofibras, a degradabilidade e a liberação do EGF. As CTMs utilizadas foram provenientes da polpa de dentes decíduos esfoliados humanos. Essas células foram cultivadas nos scaffolds e avaliadas conforme os testes biológicos: adesão, viabilidade, proliferação, citotoxicidade e diferenciação neural. Os scaffolds com fibras alinhadas controle (AC) e contendo o EGF (AE) apresentaram morfologia, diâmetro das nanofibras e tempo de degradação semelhantes. Com base no total de EGF presente na matriz AE, 90,14% foi liberado após 28 dias. O citoesqueleto e o núcleo das CTMs cultivadas nos scaffolds AC e AE estavam mais alongados e alinhados quando comparado com as CTMs cultivadas no poço de cultura (controle). As CTMs aderiram mais nas matrizes AE em relação às matrizes AC, porém a proliferação e viabilidade celular foram similares, exceto no tempo de 72 horas, o qual a viabilidade no grupo controle foi maior, em comparação aos demais grupos. Os scaffolds AC e AE não foram tóxicos para as CTMs. Em relação aos resultados da neuro-diferenciação, a expressão de nestina e neurofilamentos consideravelmente maior em todos os grupos analisados quando comparado ao grupo controle. A expressão de βIII-tubulina e GFAP foi maior em todos os grupos diferenciados quando comparada ao grupo controle. A maioria das CTMs cultivadas nas matrizes AC e AE, induzidas ou não à diferenciação neural, apresentaram correntes dependente de voltagem para sódio. O valor de condutância máxima foi maior para todos os grupos analisados quando comparado ao grupo controle onde as células não foram diferenciadas. Portanto, as matrizes com nanofibras orientadas induzem à diferenciação neural das CTMs em neurônios funcionais tanto na ausência como na presença de EGF incorporado. As matrizes AE ainda mostraram ser capazes de melhorar a adesão celular. Dessa forma, conclui-se que as matrizes de nanofibras estudadas são uma possível estratégia para otimização da regeneração de lesões neurológicas. / Damage to the central nervous system (CNS) results in loss of axonal connections and motor and sensory functions. One of the strategies for its repair is the transplantation of mesenchymal stem cells (MSCs). However, this requires a suitable application route. Accordingly, the use of scaffolds support the growth of MSCs and, when incorporated with growth factors, optimize the regeneration process. The purpose of this study was to evaluate the neural differentiation of MSCs cultured on nanofiber matrices oriented with epidermal growth factor (EGF) incorporated. Aligned scaffolds were produced by electrospinning emulsion and evaluated according to their degradation, the morphology and diameter of the nanofibers, and release of EGF from the nanofibers. MSCs used were from human exfoliated deciduous teeth (SHED). These cells were cultured on the scaffolds and evaluated according to biological tests: adhesion, viability, proliferation, cytotoxicity and neural differentiation. The aligned control scaffolds (AC) containing EGF (AE) presented similar morphology, diameter of nanofibers and degradation time. Based on the total EGF present in the scaffold AE, 90.14% was released after 28 days. The cytoskeleton and the core of the MSCs cultured on scaffolds AC and AE were more aligned and elongated when compared to the MSCs grown on plate wells (control). MSCs adhered more to matrices AE when compared to matrices AC, although proliferation and cell viability were similar, except after 72 hours. In this period, the viability of the control group was higher when compared to the rest of the groups. Scaffolds AC and AE were not toxic to MSCs. In regard to the results of neuro-differentiation, the expression of nestin and neurofilament was much higher in all groups than the control group. The expression of βIII tublin and GFAP was higher in all differentiated groups than the control group. Most of the MSCs grown in matrices AC and AE, induced or not to neural differentiation, showed voltage-dependent sodium currents. The maximum value of conductance of these groups was higher for the cells in all groupscompared to the control group, where the cells were not differentiated. Therefore, oriented nanofiber matrices induce neural differentiation of MSCs into functional neurons both in the absence and in the presence of incorporated EGF. The matrices AE also showed improved cell adhesion. Thus, these matrices are a possible strategy for optimizing the regeneration of neurologic lesions.

Introdução: O Erlotinibe é um inibidor oral da tirosina quinase localizada no domínio intracelular do receptor do fator de crescimento epidérmico (EGFR). É uma droga ativa contra o carcinoma epidermóide de cabeça e pescoço (CECCP) que apresenta alta expressão deste receptor, demonstrando desta forma possível sinergismo com a quimioterapia e a radioterapia. Objetivo: Avaliar a expressão do EGFR e da proteína Akt fosforilada por imuno-histoquímica como fator preditivo a resposta terapêutica ao Erlotinibe em um estudo fase II que incluiu 32 pacientes com CECCP localmente avançado; também foram analisados mutações do gene EGFR nos éxons 18,19,20 e 21. Pacientes e métodos: Neste estudo pacientes portadores de CECCP localmente avançado foram tratados com uma combinação de Cisplatina 100mg/m2 intravenoso, administrada nos dias 8, 29 e 50 do tratamento; e radioterapia na dose de 70 Gy administrada em 39 frações a partir do dia 8. O Erlotinibe foi iniciado uma semana antes da radioterapia e mantido até o último dia da radioterapia. Biópsias pré-tratamento, extraídas dos blocos de parafina, foram analisadas por imunohistoquímica para avaliar a expressão do EGFR e da Akt fosforilada. O resultado dessas amostras foi quantificado por um programa de análise digital de imagem. O status mutacional do gene EGFR (nos éxons 18, 19,20 e 21) foi analisado utilizando PCR convencional e sequenciamento. Resultados: A resposta completa ao tratamento ocorreu em vinte pacientes (62,5%), sendo que dois foram tratados com Laringectomia de resgate e ficaram sem evidência de doença. A análise de sobrevida com relação ao estadiamento e com o sítio anatômico evidenciou diferença estatisticamente significativa (p= 0.05). A análise das proteínas EGFR e p-Akt por imuno-histoquímica, quando os sítios estavam agrupados não apresentou valor preditivo de resposta ao tratamento; no entanto ao avaliarmos os sítios anatômicos separadamente, apenas a quantificação de EGFR em hipofaringe foi uma variável preditiva de resposta ao tratamento com erlotinibe (p=0.05). Em relação às análises moleculares nenhuma mutação foi detectada no seqüenciamento dos éxons estudados da proteína EGFR. Conclusão: A expressão do EGFR parece ser um fator preditivo à reposta terapêutica, no entanto outros estudos com identificação de outros biomarcadores e amostras maiores são necessários para elucidar quais pacientes com CECCP podem ser beneficiados com este tratamento / Purpose: Erlotinib, an oral tyrosine-kinase inhibitor, is active against squamous cell carcinoma of the head and neck (HNSCC) and possibly has a synergistic interaction with chemotherapy and radiotherapy. We investigated the expression of EGFR and phosphorylated AKT by immunohistochemistry as predictors of response to Erlotinib in a cohort of 32 locally advanced HNSCC, enrolled in a Phase II trial. In addition, we assessed mutation on hotspots of EGFR gene (exons18,19,20,21). Patients and Methods: This study was conducted in a Phase I/II trial of cisplatin 100 mg/m2 on days 8, 29 and 50; and radiotherapy 70 Gy starting on day 8. Erlotinib was started orally 1 week before chemo radiation and continued daily just to the last day of chemo radiation. Pretreatment archival tumor specimens were evaluated for EGFR and phosphorylated-Akt (p-Akt) by immunohistochemistry. These immunostains were quantified by digital image analysis. EGFR gene mutational status was also assessed using conventional PCR and sequencing. Results: Complete response to treatment occurred in twenty patients (62.5%), and two were treated with salvage laryngectomy and were without evidence of disease. Survival analysis in relation to the staging and the tumor site showed a statistically significant difference (p = 0.05). Analysis of EGFR protein and p-Akt by immunohistochemistry, when sites were grouped showed no predictive value for treatment response, however when evaluating the anatomical sites separately, only the quantification of EGFR in the hypopharynx was a significant predictor of response to treatment with erlotinib (p = 0.05). Regarding the molecular analysis no mutations were detected in the sequencing of the exons studied EGFR protein. Conclusion: The expression of EGFR seems to be a predictive factor for response to therapy, although other studies with identification of other biomarkers and larger samples are needed to elucidate which patients may benefit HNSCC with this treatment

<p>Midgut carcinoid tumours are rare with an incidence of 0.5-2.1/100 000. The primary tumour is usually small and grows slowly but has almost always set metastases at diagnosis. When radically operated, most patients will eventually recur in their disease. </p><p>We evaluated different methods in detecting recurrent disease in 61 malignant midgut carcinoid tumours that had been radically operated. Thirty-eight patients have been diagnosed with a recurrence. In 32/38 of these patients P-Chromogranin A was the first method to indicate a recurrence. We therefore recommend using P-CgA in the work up in these patients.</p><p>We investigated characteristics, survival and independent factors that could be of bad prognostic value. We found that in our 284 malignant midgut carcinoid tumours, 208/284 (73%) had distant metastases and 30/284 (11%) had carcinoid heart disease. Median survival was 115.5 months and five-year survival was 77%. In a multivariate analysis liver metastases and carcinoid heart disease were poor prognostic factors.</p><p>We performed a phase II study with octreotide pamoate investigating the clinical effect in 12 malignant midgut carcinoid tumours in a progressive phase. We found that 9/12 (75%) were stabilised for a median duration of 12 months. We think that this is a good effect considering the advanced stage.</p><p>We investigated the frequency of four different tyrosine kinase receptors, platelet derived growth factor receptor (PDGR) α and β, epidermal growth factor receptor (EGFR) and c-kit, in 36 malignant midgut carcinoid tumours with immunohistochemistry. We found that 13/34 (38%) tumour samples expressed PDGFRα, 29/33 (88%) PDGFRβ, 24/33 (73%) EGFR, whereas none expressed c-kit. This implicates that midgut carcinoid tumours might be susceptible to treatment with tyrosine kinase receptor inhibitors. </p>

The membrane mucin Muc4 is a heterodimer, bi-functional glycoprotein complex that is normally expressed in epithelial tissue. Functional studies on the extracellular mucin subunit of Muc4 have shown that it acts to promote anti-adhesion properties by sterically interfering with cell-cell and cell-matrix interactions and that the extent of this effect is directly associated with the number of tandem repeats on this subunit. Functional studies on the transmembrane subunit of Muc4 have shown that this subunit participates in intracellular signaling through interaction with the receptor tyrosine kinase ErbB2. This role of Muc4 was shown to be mediated by stabilizing the heregulin ligand-induced ErbB2-ErbB3 heterodimer through interference with the internalization process of these receptors, thus potentiating the PI3K, a survival-signaling pathway that is mediated by this heterodimer. However, Muc4 was also shown to potentiate ErbB2 phosphorylation in the absence of heregulin by an unknown mechanism. The aim of this work was to examine the role of Muc4 in intracellular signaling by evaluating the ligand-independent Muc4-ErbB2 interaction. Biochemical analyses of A375 human melanoma cells expressing Muc4 under different cell treatments, and probed with phospho-specific antibodies, were used to understand the mechanism. An antibody microarray screen was used to decipher the intracellular activated signaling pathways. The results of the mechanistic analysis indicated that Muc4 potentiates ErbB2 signaling significantly by interacting with ErbB2 and ErbB3 and by stabilizing the kinase active ErbB2 receptor, thus increasing its phosphorylation signal half-life and resulting in sustained ErbB2 signaling. The signaling pathway analysis suggests that through Muc4 direct interaction with ErbB2, signaling pathways that promote loss of cell polarity are activated. Loss of cell-cell adhesion is mediated by interference with the cadherin-catenin complex stability, and loss of cell-matrix adhesion is mediated by facilitating focal adhesion turnover. Together, these results suggest that Muc4 is a potent oncogenic factor, and further enhance our understanding of the role that Muc4 plays in ligand-independent intracellular signaling.

Midgut carcinoid tumours are rare with an incidence of 0.5-2.1/100 000. The primary tumour is usually small and grows slowly but has almost always set metastases at diagnosis. When radically operated, most patients will eventually recur in their disease. We evaluated different methods in detecting recurrent disease in 61 malignant midgut carcinoid tumours that had been radically operated. Thirty-eight patients have been diagnosed with a recurrence. In 32/38 of these patients P-Chromogranin A was the first method to indicate a recurrence. We therefore recommend using P-CgA in the work up in these patients. We investigated characteristics, survival and independent factors that could be of bad prognostic value. We found that in our 284 malignant midgut carcinoid tumours, 208/284 (73%) had distant metastases and 30/284 (11%) had carcinoid heart disease. Median survival was 115.5 months and five-year survival was 77%. In a multivariate analysis liver metastases and carcinoid heart disease were poor prognostic factors. We performed a phase II study with octreotide pamoate investigating the clinical effect in 12 malignant midgut carcinoid tumours in a progressive phase. We found that 9/12 (75%) were stabilised for a median duration of 12 months. We think that this is a good effect considering the advanced stage. We investigated the frequency of four different tyrosine kinase receptors, platelet derived growth factor receptor (PDGR) α and β, epidermal growth factor receptor (EGFR) and c-kit, in 36 malignant midgut carcinoid tumours with immunohistochemistry. We found that 13/34 (38%) tumour samples expressed PDGFRα, 29/33 (88%) PDGFRβ, 24/33 (73%) EGFR, whereas none expressed c-kit. This implicates that midgut carcinoid tumours might be susceptible to treatment with tyrosine kinase receptor inhibitors.

In this work we report that potato carboxypeptidase inhibitor suppresses the growth of several human and mouse pancreatic adenocarcinoma cell lines. The inhibitor also reduces the growth of solid tumors obtained by subcutaneous injection of human adenocarcinoma cell line in nude mice and the appearance of metastasis in mice injected intraesplenically with B16H10 melanoma cells. A transgenic line has been characterized, mice develop choroid plexus carcicomas and insulinomas. Lifespan of animals immunized with PCI I s significantly higher than control mice. To further characterize the effects of PCI on tumor cell growth, analyses of cell cycle phase distribution have been performed. A significant increase in the G0/G1 phase is also detected. This finding is correlated with an increase in the mRNA expression of p53. Moreover, we have demonstrated that PCI is easily internalized by the cells and the inhibitor remain altered after the internalization / En el presente trabajo se ha demostrado que el inhibidor de carboxipeptidasa de patata (PCI) tiene un efecto inhibitorio sobre el crecimiento tumoral tanto in vitro como in vivo, y se ha estudiado su mecanismo de acción, lo que ha llevado a descubrir que el PCI es un antagonista del EGF. Con dicho fin se han utilizado técnicas de cultivo celular en conjunción con técnicas bioquímicas, de biología molecular, de análisis computacional y ensayos con modelos animales / En el present treball s’ha demostrat que l’inhibidor de carboxipeptidasa de patata (PCI) té un efecte inhibitori sobre el creixement tumoral tant in vitro com in vivo i s’ha estudiat el seu mecanisme d’acció, que ha permès descobrir que el PCI és un antagonista de l’EGF. Amb aquest fi s’han utilitzat tècniques de cultiu cel·lular amb tècniques bioquímiques, de biologia molecular, d’anàlisi computacional i assajos amb models animals

The incidence of breast cancer became the most common female cancer, and the fourth cause of female cancer death. In this study, matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF/MS) have been combined with multivariate statistics to investigate breast cancer tissues and cell lines. Core needle biopsy and fine needle aspiration (FNA) are techniques largely applied in the diagnosis of breast cancer. In this study, we have established an efficient protocol for detecting breast tissue and FNA samples with MALDI-TOF/MS. With the help of statistical analysis software, we can find the lipid-derived ion signals which can be use to distinguish breast cancer tumor tissues from non-tumor parts. This strategy can differentiate normal and tumor tissue, which is potential to apply in clinical diagnoses. The analysis of breast cancer tissue is challenging as the complexity of the tissue sample. Direct tissue analyses by matrix-assisted laser desorption/ionization imaging mass spectrometry (MALDI-IMS) allows us to investigate the molecular structure and their distribution while maintaining the integrity of the tissue and avoiding the loss of signals from extraction steps. Combined MALDI-IMS with statistic software, tissues can be analyzed and classified based on their molecular content which is helpful to distinguish tumor regions from non-tumor regions of breast cancer tissue. Our result shows the differences in the distribution and content of lipids between tumor and non-tumor tissue which can be supplements of current pathological analysis in tumor margins. In this study, MALDI-TOF/MS combined with multivariate statistics were used to rapidly differentiate breast cancer cell lines with different estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2) status. The protocol for efficiently detecting peptides and proteins in breast cancer cells with MALDI-TOF/MS was established, two multivariate statistics including principle component analysis (PCA) and hierarchical clustering analysis were used to process the obtaining MALDI mass spectra of six different breast cancer cell lines and one normal breast cell lines. Based on the difference of the peptide and protein profiles, breast cancer cell lines with same ER and HER-2 status were grouped in nearby region on the PCA score plot. The results of hierarchical cluster analysis also revealed high conformity between breast cancer cell protein profiles and respective hormone receptor types.